slides · global inventory
Aida
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 3,551
Current window 2,041-2,070
Pages 119
Rows per page 30
Arc
2,041-2,070 of 3,551
08
The table presents financial data in thousands of dollars for the quarters ended June 30, 2023 and 2022.HeartBeam | Results Presentation Deck | 10 slides · HeartBeam
Conference presentation Investor relations Beat · DesireLoop · Why Now1 hit
09
HeartBeam | Results Presentation Deck | 10 slidesHeartBeam | Results Presentation Deck | 10 slides · HeartBeam
Conference presentation Investor relations Beat · ActionLoop · Quick Win Big Bet1 hit
10
HeartBeam | Results Presentation Deck | 10 slidesHeartBeam | Results Presentation Deck | 10 slides · HeartBeam
Conference presentation Investor relations Beat · Action1 hit
01
Includes company logo, tagline, and date.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Attention1 hit
02
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Attention1 hit
03
The slide uses a split-layout with company identity on the left and a list of achievements on the right.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Attention1 hit
04
TPD = Targeted Protein Degradation. The slide uses a four-column layout to structure the company's value proposition.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
05
TPD stands for Targeted Protein Degradation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
06
The slide uses a dot-matrix representation to indicate therapeutic focus areas for specific drug candidates.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
07
The slide uses a Gantt-chart style layout to show the progression of various drug programs.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
08
Kymera | Investor Presentation Deck | 60 slidesKymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · InterestLoop · Logic Chain1 hit
09
This is a stylistic section divider slide with an abstract background.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
10
The slide uses a biological pathway diagram to illustrate the mechanism of action and a callout box for the therapeutic thesis.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
11
The slide uses a combination of a biological mechanism diagram, a market data table, and a callout box for competitive limitations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
12
The slide uses a side-by-side comparison framework to contrast healthy volunteer data with patient data.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
14
Clinical trial baseline data table.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
15
The slide provides a breakdown of patient outcomes including completion and withdrawal reasons.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
16
HS = Hidradenitis Suppurativa, AD = Atopic Dermatitis, HV = Healthy Volunteers, PK = Pharmacokinetics, PD = Pharmacodynamics, MS = Mass Spectrometry, LLOQ = Lower Limit of Quantitation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
17
The chart demonstrates therapeutic efficacy by showing post-treatment levels (Day 28) dropping below or equal to the healthy subject baseline.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
18
The slide compares cytokine inhibition across three cohorts (MAD3 Healthy Subjects, Part C AD Patients, Part C HS Patients) using two different stimuli (LPS and R848).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
19
The chart specifically visualizes IL-6 reduction over time, while the table summarizes max reduction across four markers.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
20
The slide displays 12 individual bar charts (4 for AD, 8 for HS) representing gene expression changes.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
21
Data based on N=7 patients. Includes error bars representing standard error or confidence intervals.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
22
The chart tracks patient outcomes over time, showing a shift from severe/moderate to mild categories.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
23
Includes before/after photography, clinical efficacy table, and biomarker reduction charts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
24
The slide uses a comparison table to highlight efficacy metrics (EASI, Pruritus NRS) across different time points and benchmarks.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · DesireLoop · Aha Moment1 hit
25
Data presented for All HS Patients (N=12) and Moderate to Severe (N=10) subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
26
Data presented across three line charts comparing 'All HS Patients' vs 'Moderate to Severe' subgroups.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
27
The charts demonstrate a shift from higher severity scores (orange/red) to lower severity scores (blue/black) over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit